April 14, 2021

launch of second phase of study looking at COVID-19 heterologous prime-boost vaccination

Yesterday we hosted a briefing for science and health journalists on the extension to the COMCOV trial; a trial to investigate ‘mixing’ vaccine schedules between Pfizer-BioNTech and Oxford-AstraZeneca. Known as COMCOV2, this trial will recruit adults aged 50 and over who have had their first (prime) vaccination in the last couple of months. There were no results to discuss, this was simply the start of the trial being announced ahead of recruitment where the Chief Investigator was able to explain which vaccines have been chosen and why. 

Speakers included:

Prof Matthew Snape, Associate Professor in paediatrics and vaccinology, Oxford Vaccine Group, Chief Investigator on the trial